Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma

Drugs
Yvette N Lamb

Abstract

Intravenous elotuzumab (Empliciti™), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in previously-treated adult patients. In the pivotal, multinational, phase III ELOQUENT-2 trial in adults with relapsed and/or refractory multiple myeloma, elotuzumab in combination with lenalidomide and dexamethasone significantly prolonged median progression-free survival (PFS) and increased overall response rate (ORR; co-primary endpoints) compared with lenalidomide and dexamethasone alone. The clinical benefit of elotuzumab was maintained over the longer term (≤ 4 years' minimum follow-up); final overall survival data are awaited. Health-related quality of life was not negatively impacted by the addition of elotuzumab. Elotuzumab combination therapy had a generally manageable tolerability profile and the most common adverse events (AEs) of grade ≥ 3 severity were haematological (e.g. lymphocytopenia, anaemia, thrombocytopenia, neutropenia). Elotuzumab plus lenalidomide and dexamethasone extends the treatment options available for the management of relapsed and/or refractory mul...Continue Reading

References

May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric D HsiMarna B Williams
Sep 11, 2009·Nature Biotechnology·Malorye Allison
Oct 8, 2014·Cancer Immunology, Immunotherapy : CII·Balaji BalasaAudie G Rice
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Mar 20, 2016·Journal of Pharmacokinetics and Pharmacodynamics·Leonid GibianskyManish Gupta
Jul 2, 2016·Journal of Hematology & Oncology·Leonard Naymagon, Maher Abdul-Hay
Apr 15, 2018·Molecular Cancer Therapeutics·Ahmed T KurdiIrene M Ghobrial

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.